Shanghai Yizhong Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd. Free Cash Flow Per Share for the year ending December 31, 2023: USD 0.05

Shanghai Yizhong Pharmaceutical Co., Ltd. Free Cash Flow Per Share is USD 0.05 for the year ending December 31, 2023, a -22.37% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Shanghai Yizhong Pharmaceutical Co., Ltd. Free Cash Flow Per Share for the year ending December 31, 2022 was USD 0.07, a 232.82% change year over year.
Shanghai Yizhong Pharmaceutical Co., Ltd. Free Cash Flow Per Share for the year ending December 31, 2021 was USD -0.05, a -111.56% change year over year.
Shanghai Yizhong Pharmaceutical Co., Ltd. Free Cash Flow Per Share for the year ending December 31, 2020 was USD -0.02, a 62.37% change year over year.
Shanghai Yizhong Pharmaceutical Co., Ltd. Free Cash Flow Per Share for the year ending December 31, 2019 was USD -0.06, a -229.83% change year over year.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

Shanghai Stock Exchange: 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd.

CEO	Mr. Jingsong Zhou
IPO Date	Sept. 9, 2021
Location	China
Headquarters	No.79 Renqi Road
Employees	304
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It develops a dosage form of paclitaxel, an anti-tumor chemotherapeutic. The company was founded in 2009 and is based in Shanghai, China.

Key trends

Past 5 years